338 related articles for article (PubMed ID: 32984034)
1. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Tian Z; Niu X; Yao W
Front Oncol; 2020; 10():1642. PubMed ID: 32984034
[TBL] [Abstract][Full Text] [Related]
2. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
[TBL] [Abstract][Full Text] [Related]
3. Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update.
Greenfield EM; Collier CD; Getty PJ
Adv Exp Med Biol; 2020; 1258():141-155. PubMed ID: 32767239
[TBL] [Abstract][Full Text] [Related]
4. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.
Rettew AN; Young ED; Lev DC; Kleinerman ES; Abdul-Karim FW; Getty PJ; Greenfield EM
Oncogenesis; 2012 Nov; 1(11):e34. PubMed ID: 23552467
[TBL] [Abstract][Full Text] [Related]
5. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma.
Fleuren EDG; Vlenterie M; van der Graaf WTA
Front Oncol; 2023; 13():1013359. PubMed ID: 36994209
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Huang L; Fu L
Acta Pharm Sin B; 2015 Sep; 5(5):390-401. PubMed ID: 26579470
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.
Assi A; Farhat M; Hachem MCR; Zalaquett Z; Aoun M; Daher M; Sebaaly A; Kourie HR
J Bone Oncol; 2023 Dec; 43():100511. PubMed ID: 38058514
[TBL] [Abstract][Full Text] [Related]
8. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
[TBL] [Abstract][Full Text] [Related]
9. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
10. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.
de Rosamel L; Blanc JF
Expert Opin Emerg Drugs; 2017 Jun; 22(2):175-190. PubMed ID: 28604110
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinases and targeted cancer therapeutics.
Takeuchi K; Ito F
Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
[TBL] [Abstract][Full Text] [Related]
12. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
Demetri GD
Semin Oncol; 2011 Apr; 38 Suppl 1():S10-9. PubMed ID: 21419931
[TBL] [Abstract][Full Text] [Related]
13. Activation Status of Receptor Tyrosine Kinases as an Early Predictive Marker of Response to Chemotherapy in Osteosarcoma.
Chaiyawat P; Klangjorhor J; Settakorn J; Champattanachai V; Phanphaisarn A; Teeyakasem P; Svasti J; Pruksakorn D
Transl Oncol; 2017 Oct; 10(5):846-853. PubMed ID: 28881260
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I; Balek L; Varecha M; Kucerova JF; Kunova Bosakova M; Fafilek B; Palusova V; Uldrijan S; Trantirek L; Krejci P
Oncotarget; 2017 Dec; 8(65):109319-109331. PubMed ID: 29312610
[TBL] [Abstract][Full Text] [Related]
15. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.
Grüllich C
Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760
[TBL] [Abstract][Full Text] [Related]
17. Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-derived Growth Factor Receptor (PDGFR) Kinase Inhibitors.
Qian Y; Yu L; Zhang XH; Yuan ZQ; Zhao P; Sun LN; Wang YQ
Curr Drug Metab; 2018; 19(14):1168-1181. PubMed ID: 29956623
[TBL] [Abstract][Full Text] [Related]
18. Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma.
Chen C; Shi Q; Xu J; Ren T; Huang Y; Guo W
Cell Death Discov; 2022 Dec; 8(1):488. PubMed ID: 36509754
[TBL] [Abstract][Full Text] [Related]
19. Overcoming therapeutic failure in osteosarcoma
Li X; Wang L; Wang L; Yu J; Lu G; Zhao W; Miao C; Zou C; Wu J
Biomater Sci; 2020 Oct; 8(21):5888-5899. PubMed ID: 33001086
[TBL] [Abstract][Full Text] [Related]
20. Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.
Spanheimer PM; Lorenzen AW; De Andrade JP; Kulak MV; Carr JC; Woodfield GW; Sugg SL; Weigel RJ
Ann Surg Oncol; 2015 Dec; 22(13):4287-94. PubMed ID: 25971960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
